Biotek-snakken — December 2020

[rur]

Norske Bergenbio har data readout på AML indikation, med positive resultater. Abstract tilgængelig for præsentation 6/12: https://ash.confex.com/ash/2020/webprogram/Paper136566.html

[bibob]

OncLive. : Zanidatamab. https://www.onclive.com/view/fda-grants-zanidatamab-breakthrough-status-in-her2-biliary-tract-cancer?utm_source=sfmc&utm_medium=email&utm_campaign=11-30-20_JAN-19-OGD0730_OncLiveSS_MCL CC eNews_Imbruvica,Janssen_NON_US_Send&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ== Til dem der ikke har adgang til Sukkers link.

[lahn1]

Tak Bibob, du er en ven af folket

[Sukkeralf]

Det er no ikke helt samme artikel - her lige et par punkter fra mit link:

[Sukkeralf]

"This is a really good drug. It has received the orphan designation [in Europe]. We have [also] worked with zanidatamab and you will see some data from us at the ASCO GI [The Gastrointestinal Cancers Symposium, January 15-17, 2021]. It's a multi-institutional trial. We get a lot of responses with this drug. It's also targeting the HER2-positive population. And certainly, it is not as toxic as Enhertu, which is a pretty toxic drug."

[Sukkeralf]

"In fact this molecule is going to go into Phase III first-line and they're working with a Chinese company called BeiGene. So BeiGene is partnering with Zymeworks. In terms of the trial design it should be compared to Herceptin plus chemotherapy versus zanidatamab plus chemotherapy. And that will be a third arm, which will be zanidatamab and BeiGene's own PD-1 inhibitor, tislelizumab and chemotherapy.

[Sukkeralf]

And I expect it to succeed because zanidatamab is a really good drug. I have personal experience with this drug and it is so much better than Herceptin. I think it will beat Herceptin very easily."

[Sukkeralf]

Nu er det sjældent vi ser head to head studier, så det virker ret overbevisende, når en KOL mener at zanidatamab nemt kan slå Herceptin

[lahn1]

Meget positivt, hvem udtaler sig ?

[Sukkeralf]

FirstWord recently spoke to Jaffer Ajani – Professor of Medicine at the University of Texas MD Anderson Cancer Centre – to discuss the ongoing development of zanidatamab in this setting.

[lahn1]

Bergenbio - ikke så ringe endda 1L umiddelbart en god mDOR 17,3 mdr. og 2 CR ongoing. Totalt 43% CR (3/7) til sammenligning uden at kunne sammen ligne havde Venclexta + AZA i PH3 1L 14,7 mdr mOS, 65% CR men holder ikke så længe mDOCR 18 mdr.

[lahn1]

Tak sukker

[lahn1]

Bergenbio - 2 L relapsed "udbygger vs cohort 3B" ORR fra 25% (1/4) til ORR 50% (4/8) og fastholder CR 25% men har også 1 CRi + 1PR. 2SD 6/8 75% CB.

[lahn1]

Jo længere tid der går før vi får OS, jo bedre, men er lidt utålmodig og vil gerne have bekræftet hvad jeg går og drømmer om :-). Bemcentinib the new corner stone in combination cancer therapy

[lahn1]

ZYME - Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGene
Zymeworks to receive US$10 million milestone payment from BeiGene

[Rasbom]

Immunovia: Er der noget som kender grunden til Immunovias store kursfald i dag på 20%. Jeg kan ikke se at selskabet er kommet med nogen meddelelser.

[Torbenbf]

Paa Placeras Immunovia forum skriver de at denne artikel er skylden: https://www.di.se/live/diagnostikbolagets-aktie-pressas-efter-di-s-granskning/

[Rasbom]

Tak for svar Torvenbf.

[BioShare]

Cellectar - besynderlig tur fra minus i kurs 1,18 op i 1,77 og nu ned i 1,43 wtf

[lahn1]

Ja underlig tur. Har du set på Actinium ? Undre mig at disse to radioaktive kandidater CLRB og ATNM er så lavt prissat. Er der noget jeg ikke forstår ?